The studies focus on the Brainomix 360 e-Lung platform, an FDA-cleared and CE-marked tool designed to automate the quantification of radiographic features in lung scans. By providing objective data, the technology aims to support clinicians in assessing treatment response, identifying early disease progression, and stratifying mortality risk in patients with fibrotic conditions.

Prof. Peter George, a consultant at London’s Royal Brompton Hospital and Senior Medical Director at Brainomix, emphasized that these findings strengthen the integration of imaging biomarkers into routine clinical practice. The presentations, scheduled between September 6 and September 8, cover diverse clinical applications including the validation of risk thresholds, the correlation between telomere shortening and reticulovascular burden, and the identification of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.